Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's diseaseDE LAGO, Eva; URBANI, Paolo; RAMOS, José Antonio et al.Brain research. 2005, Vol 1050, Num 1-2, pp 210-216, issn 0006-8993, 7 p.Article

Effect of arvanil (N-arachidonoyl-vanillyl-amine), a nonpungent anandamide-capsaicin hybrid, on ion currents in NG108-15 neuronal cellsLO, Yuk-Keung; CHIANG, Hung-Ting; WU, Sheng-Nan et al.Biochemical pharmacology. 2003, Vol 65, Num 4, pp 581-591, issn 0006-2952, 11 p.Article

Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB₁/CB₂ receptorsBROOKS, Jason W; PRYCE, Gareth; DI MARZO, Vincenzo et al.European journal of pharmacology. 2002, Vol 439, Num 1-3, pp 83-92, issn 0014-2999Article

Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amideDI MARZO, Vincenzo; BREIVOGEL, Christopher; BISOGNO, Tiziana et al.European journal of pharmacology. 2000, Vol 406, Num 3, pp 363-374, issn 0014-2999Article

The CB1/VR1 agonist arvanil induces apoptosis through an FADD/caspase-8-dependent pathwaySANCHO, Rocio; DE LA VEGA, Laureano; APPENDINO, Giovanni et al.British journal of pharmacology. 2003, Vol 140, Num 6, pp 1035-1044, issn 0007-1188, 10 p.Article